Journal article · 2026

Interleukin-6 Inhibition with Ziltivekimab for Atherosclerotic Disease

Paul M. Ridker, Abraham Michael Lincoff, Nikolaus Marx, Ann Marie Návar, Naveed A. Sattar, Katherine R. Tuttle, Matthew Budoff, Morten Bøttcher, Matthew Aaron Cavender, Robin P. Choudhury, Jan Hein Cornel, Grzegorz Gajos and 21 more

New England Journal of Medicine · Published 7 November 2026 · DOI 10.1056/nejmoa2612126

View at the publisherCite this paper

In brief

“Interleukin-6 Inhibition with Ziltivekimab for Atherosclerotic Disease” is a 2026 journal article by Paul M. Ridker and 32 co-authors, published in New England Journal of Medicine. OpenAlex counts 1 citations as of 16 November 2026, which puts it in the top 9% of works published in 2026 by citations. The publisher's version is not open access, and OpenAlex records no free legal copy.

Citations
1
Most cited in
2026 (1)
Field-weighted impact
1.90
References
36
Authors
33

Abstract

BACKGROUND: The inflammatory cytokine interleukin-6 is hypothesized to be a therapeutic target for patients with atherosclerotic cardiovascular disease and chronic kidney disease. Whether neutralizing interleukin-6 levels with ziltivekimab, a monoclonal antibody, reduces the risk of adverse cardiovascular events remains unknown. METHODS: We conducted a multinational, double-blind, randomized, placebo-controlled trial involving adults with established atherosclerotic cardiovascular… Read the full abstract at the publisher.

Excerpt. This paper is not open access.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Ridker, P. M., Lincoff, A. M., Marx, N., Návar, A. M., Sattar, N. A., Tuttle, K. R., Budoff, M., Bøttcher, M., Cavender, M. A., Choudhury, R. P., Cornel, J. H., Gajos, G., Komuro, I., Parvathareddy, K. R., Pontremoli, R., Saraiva, J. F. K., Simova, I. I., Sloan, L. A., López-Suárez, A., . . . Perkovic, V. (2026). Interleukin-6 Inhibition with Ziltivekimab for Atherosclerotic Disease. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2612126

MLA 9

Ridker, Paul M., et al. “Interleukin-6 Inhibition with Ziltivekimab for Atherosclerotic Disease.” New England Journal of Medicine, 2026. https://doi.org/10.1056/nejmoa2612126.

Chicago

Ridker, Paul M., Abraham Michael Lincoff, Nikolaus Marx, Ann Marie Návar, Naveed A. Sattar, Katherine R. Tuttle, Matthew Budoff, et al. 2026. “Interleukin-6 Inhibition with Ziltivekimab for Atherosclerotic Disease.” New England Journal of Medicine. https://doi.org/10.1056/nejmoa2612126.

Harvard

Ridker, P. M. et al. (2026) ‘Interleukin-6 Inhibition with Ziltivekimab for Atherosclerotic Disease’, New England Journal of Medicine. doi:10.1056/nejmoa2612126.

IEEE

P. M. Ridker et al., “Interleukin-6 Inhibition with Ziltivekimab for Atherosclerotic Disease,” New England Journal of Medicine, 2026, doi: 10.1056/nejmoa2612126.

BibTeX

@article{ridker2026interleukin,
  title     = {{Interleukin-6 Inhibition with Ziltivekimab for Atherosclerotic Disease}},
  author    = {Ridker, Paul M. and Lincoff, Abraham Michael and Marx, Nikolaus and Návar, Ann Marie and Sattar, Naveed A. and Tuttle, Katherine R. and Budoff, Matthew and Bøttcher, Morten and Cavender, Matthew Aaron and Choudhury, Robin P. and Cornel, Jan Hein and Gajos, Grzegorz and Komuro, Issei and Parvathareddy, K.M.K. Reddy and Pontremoli, Roberto and Saraiva, José Francisco Kerr and Simova, Iana Ivaylova and Sloan, Lance Alan and López-Suárez, Alejandro and Tang, Yi-Da and Tokgözoğlu, Lale and Tsabedze, Nqoba and Tsioufis, Konstantinos and Verma, Subodh and Vrolix, Mathias and Andersen, Andreas and Baeres, Florian M.M. and Ekström, Kathrine and Engelmann, Mads D.M. and Gerward, Sofia and others},
  journal   = {New England Journal of Medicine},
  year      = {2026},
  doi       = {10.1056/nejmoa2612126},
  url       = {https://doi.org/10.1056/nejmoa2612126}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases

  • IL-6 inhibition
  • atherosclerotic cardiovascular disease
  • chronic kidney disease
  • cardiovascular inflammation
  • high-sensitivity C-reactive protein
  • major adverse cardiovascular events
  • serious infections
  • anti-inflammatory therapy

Work with this paper

Most-cited papers in Immunology and Microbiology

All highly cited Immunology and Microbiology papers

Questions about this paper

How do I cite this paper in APA style?

Ridker, P. M., Lincoff, A. M., Marx, N., Návar, A. M., Sattar, N. A., Tuttle, K. R., Budoff, M., Bøttcher, M., Cavender, M. A., Choudhury, R. P., Cornel, J. H., Gajos, G., Komuro, I., Parvathareddy, K. R., Pontremoli, R., Saraiva, J. F. K., Simova, I. I., Sloan, L. A., López-Suárez, A., . . . Perkovic, V. (2026). Interleukin-6 Inhibition with Ziltivekimab for Atherosclerotic Disease. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2612126

How many times has this paper been cited?

1 times, according to OpenAlex on 16 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

OpenAlex records no free legal copy. Check your library's access, the authors' pages or a repository, or ask the corresponding author for a copy.

Who wrote this paper?

Paul M. Ridker, Abraham Michael Lincoff, Nikolaus Marx, Ann Marie Návar, Naveed A. Sattar, Katherine R. Tuttle, Matthew Budoff, Morten Bøttcher, Matthew Aaron Cavender, Robin P. Choudhury, Jan Hein Cornel, Grzegorz Gajos and 21 more.

What is the DOI of this paper?

10.1056/nejmoa2612126, permanently at https://doi.org/10.1056/nejmoa2612126. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 16 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.